Edition:
United States

Biomarin Pharmaceutical Inc (BMRN.OQ)

BMRN.OQ on NASDAQ Stock Exchange Global Select Market

98.09USD
4:00pm EDT
Change (% chg)

$6.07 (+6.60%)
Prev Close
$92.02
Open
$91.58
Day's High
$98.70
Day's Low
$90.53
Volume
1,433,177
Avg. Vol
556,635
52-wk High
$148.29
52-wk Low
$62.22

BMRN.OQ

Chart for BMRN.OQ

About

BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company's product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha),... (more)

Overall

Beta: 1.08
Market Cap(Mil.): $14,936.91
Shares Outstanding(Mil.): 162.32
Dividend: --
Yield (%): --

Financials

  BMRN.OQ Industry Sector
P/E (TTM): -- 36.73 37.52
EPS (TTM): -1.18 -- --
ROI: -5.71 15.28 14.48
ROE: -8.03 16.33 15.65

BRIEF-BioMarin to provide updated data on Hemophilia drug

* Biomarin to provide updated data for BMN 270 in Hemophilia A in late breaking oral presentation at the World Federation of Hemophilia (WFH) 2016 World Congress July 27th Source text for Eikon: Further company coverage:

Jul 21 2016

BRIEF-Biomarin makes board appointments

* Biomarin appoints two biopharmaceutical veterans to board of directors, Willard Dere, M.D. And Kathryn E. Falberg Source text for Eikon: Further company coverage:

Jul 18 2016

BRIEF-Biomarin withdraws market authorization application for Kyndrisa in Europe

* Biomarin announces withdrawal of market authorization application for Kyndrisa (drisapersen) in Europe

May 31 2016

BRIEF-Biomarin Pharmaceutical announces EMA grants accelerated assessment

* Biomarin announces ema grants accelerated assessment for cerliponase alfa, experimental treatment for a form of batten disease

May 03 2016

BRIEF-Biomarin posts Q1 GAAP loss per share $0.53

* Q1 earnings per share view $-0.79 -- Thomson Reuters I/B/E/S

Apr 28 2016

BRIEF-Biomarin Q1 gaap loss per share $0.53

* Q1 earnings per share view $-0.79 -- Thomson Reuters I/B/E/S

Apr 28 2016

BRIEF-Biomarin enrolls first patient in early study of BMN 250 for sanfilippo B syndrome

* Biomarin enrolls first patient in phase 1/2 trial of NAGLU fusion protein BMN 250 for treatment of MPS IIIB (sanfilippo B syndrome)

Apr 21 2016

BRIEF-Biomarin provides program update on Vosoritide in Achondroplasia

* Biomarin provides program update on Vosoritide in Achondroplasia

Apr 20 2016

BRIEF-Biomarin provides preliminary data on first 8 patients in Hemophilia A gene therapy program

* Biomarin provides encouraging preliminary data on first 8 patients in hemophilia a gene therapy program

Apr 20 2016

BRIEF-Biomarin- gets European orphan drug designation for Gene Therapy drug for Hemophilia A

* Receives European orphan drug designation for bmn 270, first investigational aav-factor viii gene therapy for patients with hemophilia a Source text for Eikon: Further company coverage:

Mar 24 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $124.77 -0.38
Pfizer Inc. (PFE.N) $36.85 +0.02
Novartis AG (NOVN.S) CHF81.90 -0.60
Merck & Co., Inc. (MRK.N) $58.60 +0.24
Roche Holding Ltd. (ROG.S) CHF249.30 -1.00
Roche Holding Ltd. (RO.S) CHF250.00 -1.25
Abbott Laboratories (ABT.N) $43.67 +0.07
Bayer AG (BAYGn.DE) €94.62 +1.05
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €76.70 +0.13

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.